Shares of Verona Pharma plc (NASDAQ: VRNA) surged by 5.2% on Monday, November 4, 2024, following the company's impressive third-quarter 2024 financial results and updates on the successful launch of its COPD drug Ohtuvayre (ensifentrine).
For the quarter ended September 30, 2024, Verona Pharma reported net sales of $5.6 million, significantly beating analyst estimates of around $2 million. This robust revenue performance was driven by the initial launch of Ohtuvayre, which received FDA approval in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease (COPD).
According to the company, Ohtuvayre recorded over 5,000 prescriptions filled and was prescribed by more than 2,200 unique healthcare professionals across a broad COPD patient population in just the first 12 weeks of launch. Notably, Verona Pharma stated that net sales in October exceeded the third quarter, indicating continued acceleration in demand for the novel COPD therapy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。